Victory Capital Management Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Victory Capital Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 05, 2024	SELL	$38.96 - $42.75 $5,376 - $5,899	-138 Reduced 1.2%	11,317 $462,000
Q1 2024 May 03, 2024	SELL	$40.88 - $43.27 $5,600 - $5,927	-137 Reduced 1.18%	11,455 $484,000
Q4 2023 Feb 05, 2024	BUY	$20.27 - $42.44 $234,969 - $491,964	11,592 New	11,592 $491,000
Q2 2023 Jul 27, 2023	BUY	$23.9 - $35.38 $176,310 - $260,998	7,377 New	7,377 $234,000
Q4 2022 Feb 10, 2023	BUY	$25.35 - $31.96 $1,723 - $2,173	68 Added 0.9%	7,601 $239,000
Q4 2022 Feb 09, 2023	SELL	$25.35 - $31.96 $260,091 - $327,909	-10,260 Reduced 57.66%	7,533 $237,000
Q3 2022 Nov 02, 2022	SELL	$25.5 - $41.42 $42,967 - $69,792	-1,685 Reduced 8.65%	17,793 $503,000
Q2 2022 Aug 01, 2022	BUY	$20.62 - $37.15 $41,116 - $74,077	1,994 Added 11.4%	19,478 $515,000
Q1 2022 May 04, 2022	BUY	$23.5 - $35.38 $225,506 - $339,506	9,596 Added 121.65%	17,484 $512,000
Q4 2021 Feb 07, 2022	BUY	$29.21 - $44.64 $230,408 - $352,120	7,888 New	7,888 $256,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.